Brendan Hussey
Vice President JLS Fund
Seminars
Thursday 5th February 2026
Panel Discussion: Bridging Innovation & Investment: De-Risking Disease-Modifying Neurodegenerative Therapies to Secure Investor Backing
4:30 pm
- How important is it to present rigorously validated biology and clear platform expansion potential, rather than a single asset story, when seeking investment in disease modifying Alzheimer’s or Parkinson’s therapies?
- Is a biomarker driven proof of concept within roughly 24 months now viewed as the standard benchmark for funding decisions in neurodegenerative drug development?
- To what extent does a pipeline that hedges risk through multiple mechanisms, such as combining blood–brain barrier shuttle antibodies with gene or small molecule therapies, shape investment appetite in this space?
